Risks and Benefits of Multimodal Esophageal Cancer Treatments: A Meta-Analysis

about

Clinical Effect of Radiotherapy Combined with Chemotherapy for Non-Surgical Treatment of the Esophageal Squamous Cell Carcinoma.

P2860

Q55564006-1566A505-BE04-407E-AB8E-30BF38917873

P2860

Risks and Benefits of Multimodal Esophageal Cancer Treatments: A Meta-Analysis

Item

http://www.wikidata.org/entity/Q36284840

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Risks and Benefits of Multimodal Esophageal Cancer Treatments: A Meta-Analysis

@ast

Risks and Benefits of Multimodal Esophageal Cancer Treatments: A Meta-Analysis

@en

type

Item

label

Risks and Benefits of Multimodal Esophageal Cancer Treatments: A Meta-Analysis

@ast

Risks and Benefits of Multimodal Esophageal Cancer Treatments: A Meta-Analysis

@en

prefLabel

Risks and Benefits of Multimodal Esophageal Cancer Treatments: A Meta-Analysis

@ast

Risks and Benefits of Multimodal Esophageal Cancer Treatments: A Meta-Analysis

@en

P1476

Risks and Benefits of Multimodal Esophageal Cancer Treatments: A Meta-Analysis

@en

P2093

Cheng Yi

http://www.w3.org/2001/XMLSchema#string

Fen Zhao

http://www.w3.org/2001/XMLSchema#string

Lei Sun

http://www.w3.org/2001/XMLSchema#string

Yan Zeng

http://www.w3.org/2001/XMLSchema#string

P2860

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement

Non-surgical versus surgical treatment for oesophageal cancer

Preoperative chemotherapy for resectable thoracic esophageal cancer

Interventions for dysphagia in oesophageal cancer

Preoperative radiotherapy for esophageal carcinoma

Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Carcinoma of the esophagus seen in a 12-year period at Queens Hospital Center.

Randomized phase 2 trial of S1 and oxaliplatin-based chemoradiotherapy with or without induction chemotherapy for esophageal cancer.

Esophageal cancer: staging system and guidelines for staging and treatment.

P304

889-910

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.12659/MSM.903328

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28214903

http://www.w3.org/2001/XMLSchema#string

P932

5330207

http://www.w3.org/2001/XMLSchema#string

Risks and Benefits of Multimodal Esophageal Cancer Treatments: A Meta-Analysis

about

P2860

P2860

Risks and Benefits of Multimodal Esophageal Cancer Treatments: A Meta-Analysis

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932